Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines

Clinical and Vaccine Immunology

Volumn 16, Issue 5, 2009, Pages 699-705

  Bernstein, David I ^a,c   Cardin, Rhonda D ^a   Bravo, Fernando J ^a   Strasser, Jane E ^a   Farley, Nicholas ^a   Chalk, Claudia ^a   Lay, Marla ^b   Fairman, Jeff ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b Juvaris BioTherapeutics Inc   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; HERPES SIMPLEX VACCINE; JVRS 100; LIPOSOME; PHOSPHORYL LIPID A; PLASMID DNA; TREHALOSE DICORYNOMYCOLATE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; COMBINATION CHEMOTHERAPY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CELLS, CULTURED; DNA; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LIPOSOMES; MACROMOLECULAR SUBSTANCES; MICE; SPLEEN; SURVIVAL ANALYSIS; VAGINA; VIRUS REPLICATION;

EID: 66849128453     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00370-08     Document Type: Article

References (46)

1. Allen, L. B., S. M. Wolf, C. J. Hintz, J. H. Huffman, and R. W. Sidwell. 1977. Effect of ribavirin on type 2 herpesvirus hominis (HVH/2) in vitro and in vivo. Ann. N. Y. Acad. Sci. 284:247-253.
2. BenMohamed, L., G. Bertrand, C. D. McNamara, H. Gras-Masse, J. Hammer, S. L. Wechsler, and A. B. Nesburn. 2003. Identification of novel immunodominant CD4+ Th1-typeT-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77:9463-9473.
3. Bernstein, D. I., L. R. Stanberry, C. J. Harrison, R. Shukla, J. C. Kappes, and M. G. Myers. 1987. Antibody response to herpes simplex virus glycoprotein D: effects of acyclovir and relation to recurrence. J. Infect. Dis. 156:423-429.
4. Bourne, N., L. R. Stanberry, E. R. Kern, G. Holan, B. Matthews, and D. I.Bernstein. 2000. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Che-mother. 44:2471-2474.
5. Chen, C. Y., R. C. Ballard, C. M. Beck-Sague, Y. Dangor, F. Radebe, S.Schmid, J. B. Weiss, V. Tshabalala, G. Fehler, Y. Htun, and S. A. Morse.2000. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex. Transm. Dis. 27:21-29.
6. Chentoufi, A. A., X. Zhang, K. Lamberth, G. Dasgupta, I. Bettahi, A. Nguyen, M. Wu, X. Zhu, A. Mohebbi, S. Buus, S. L. Wechsler, A. B. Nesburn, and L. BenMohamed. 2008. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 180:426-437.
7. Chu, C. F., M. G. Meador, C. G. Young, J. E. Strasser, N. Bourne, and G. N. Milligan. 2008. Antibody-mediated protectionagainst genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms. J. Reprod. Immunol. 78:58-67.
8. Corey, L., A. G. Langenberg, R. Ashley, R. E. Sekulovich, A. E. Izu, J. M. Douglas, Jr., H. H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo,A. A. Adimora, P. Leone, C. L. Dekker, R. L. Burke, W. P. Leong, S. E.Straus, et al. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282:331-340.
9. Cunningham, A. L., and Z. Mikloska. 2001. The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes 8(Suppl. 1):6A-10A.
10. Cunningham, A. L., R. R. Turner, A. C. Miller, M. F. Para, and T. C.Merigan. 1985. Evolution of recurrent herpes simplex lesions. An immuno- histologic study. J. Clin. Investig. 75:226-233.
11. Dow, S. W., L. G. Fradkin, D. H. Liggitt, A. P. Willson, T. D. Heath, andT. A.Potter. 1999. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163:1552-1561.
12. Dow, S. W., J. Schwarze, T. D. Heath, T. A. Potter, and E. W. Gelfand. 1999.Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Hum. Gene Ther.10:1905-1914.
13. Dudley, K. L., N. Bourne, and G. N. Milligan. 2000. Immune protection against HSV-2 in B-cell-deficient mice. Virology 270:454-463.
14. Fairman, J., J. Moore, M. Lemieux, K. Van Rompay, Y. Geng, J. Warner, and K. Abel. 2008. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum. Vaccin. 5:1-10.
15. Freimark, B. D., H. P. Blezinger, V. J. Florack, J. L. Nordstrom, S. D. Long,D. S. Deshpande, S. Nochumson, and K. L. Petrak. 1998. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J. Immunol. 160:4580-4586.
16. Ghiasi, H., A. B. Nesburn, and S. L. Wechsler. 1996. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine 14:107-112.
17. Gupta, R., T. Warren, and A. Wald. 2007. Genital herpes. Lancet 370:2127-2137.
18. Gursel, I., M. Gursel, K. J. Ishii, and D. M. Klinman. 2001. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167:3324-3328.
19. Guy, B. 2007. The perfect mix: recent progress in adjuvant research. Nat.Rev. Microbiol. 5:505-517.
20. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses.Nature 434:772-777.
21. Hosken, N., P. McGowan, A. Meier, D. M. Koelle, P. Sleath, F. Wagener, M.Elliott, K. Grabstein, C. Posavad, and L. Corey. 2006. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J. Virol. 80:5509-5515.
22. Ishii, N., J. Fukushima, T. Kaneko, E. Okada, K. Tani, S. I. Tanaka, K.Hamajima, K. Q. Xin, S. Kawamoto, W. Koff, K. Nishioka, T. Yasuda, and K. Okuda. 1997. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 13:421-1428.
23. Johnson, A. J., C. F. Chu, and G. N. Milligan. 2008. Effector CD4+ T cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J. Virol. 82:9678-9688.
24. Kern, E. R., J. T. Richards, J. C. Overall, Jr., and L. A. Glasgow. 1977.Genital herpesvirus hominis infection in mice. II. Treatment with phospho- noacetic acid, adenine arabinoside, and adenine arabinoside 5'-monophos-phate. J. Infect. Dis. 135:557-567.
25. Kimberlin, D. W. 2007. Herpes simplex virus infections of the newborn. Semin. Perinatol. 31:19-25.
26. Koelle, D. M., and L. Corey. 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96-113.
27. Koelle, D. M., C. M. Posavad, G. R. Barnum, M. L. Johnson, J. M. Frank,and L. Corey. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin.Investig. 101:1500-1508.
28. Kwissa, M., S. P. Kasturi, and B. Pulendran. 2007. The science of adjuvants. Expert Rev. Vaccines 6:673-684.
29. Leone, P. 2005. Reducing the risk of transmitting genital herpes: advances in understanding and therapy. Curr. Med. Res. Opin. 21:1577-1582.
30. Milligan, G. N., D. I. Bernstein, and N. Bourne. 1998. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160:6093-6100.
31. Morrison, L. A. 2008. Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology 376:205-210.
32. O'Hagan, D. T., M. L. MacKichan, and M. Singh. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. 18:69-85.
33. Overall, J. C., Jr., E. R. Kern, R. L. Schlitzer, S. B. Friedman, and L. A. Glasgow. 1975. Genital herpesvirus hominis infection in mice. I. Development of an experimental model. Infect. Immun. 11:476-480.
34. Petrovsky, N., and J. C. Aguilar. 2004. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82:488-496.
35. Rupp, R., and D. I. Bernstein. 2008. The potential impact of a prophylactic herpes simplex vaccine. Expert Opin. Emerg. Drugs 13:41-52.
36. Schijns, V. E. 2003. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 21:829-831.
37. Singh, M., and D. T. O'Hagan. 2002. Recent advances in vaccine adjuvants. Pharm. Res. 19:715-728.
38. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepa- peliere, and G. Dubin. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
39. Strasser, J. E., R. L. Arnold, C. Pachuk, T. J. Higgins, and D. I. Bernstein.2000. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J. Infect. Dis. 182:1304-1310.
40. Wald, A., and L. Corey. 2003. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? J. Infect. Dis.187:1509-1512.
41. Willis, S. H., A. H. Rux, C. Peng, J. C. Whitbeck, A. V. Nicola, H. Lou, W.Hou, L. Salvador, R. J. Eisenberg, and G. H. Cohen. 1998. Examination of the kinetics of herpes simplex virus glycoprotein D binding to the herpesvirus entry mediator, using surface plasmon resonance. J. Virol. 72:5937-5947.
42. Yasuda, K., Y. Ogawa, I. Yamane, M. Nishikawa, and Y. Takakura. 2005. Macrophage activation by a DNA/cationic liposome complex requires endo- somal acidification and TLR9-dependent and -independent pathways.J. Leukoc. Biol. 77:71-79.
43. Yasuda, K., P. Yu, C. J. Kirschning, B. Schlatter, F. Schmitz, A. Heit, S.Bauer, H. Hochrein, and H. Wagner. 2005. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J. Immunol. 174:6129-6136.
44. Zaks, K., M. Jordan, A. Guth, K. Sellins, R. Kedl, A. Izzo, C. Bosio, and S. Dow. 2006. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176:7335-7345.
45. Zhu, J., D. M. Koelle, J. Cao, J. Vazquez, M. L. Huang, F. Hladik, A. Wald,and L. Corey. 2007. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp.Med. 204:595-603.
46. Zhu, N., D. Liggitt, Y. Liu, and R. Debs. 1993. Systemicgeneexpressionafter intravenous DNA delivery into adult mice. Science 261:209-211.